Tralement Versus a Fixed-dose Trace Element Combination Product of Zinc, Copper, and Selenious Acid to Evaluate Product Safety in Adult Patients Requiring Long-term Parenteral Nutrition

Sponsor

American Regent, Inc. (Industry)

Overall Status

Not yet recruiting

CT.gov ID

NCT05661682

Collaborator

(none)

108

Enrollment

Arms

47.1

Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

Tralement versus a fixed-dose trace element combination product of zinc, copper, and selenious acid to evaluate product safety in adult patients requiring long-term parenteral nutrition.

Condition or Disease	Intervention/Treatment	Phase
Manganese Safety in Adults	Drug: Tralement Drug: Fixed-dose trace element combination product of zinc, copper, and selenious acid	Phase 4

Detailed Description

A Phase IV, multi-center, randomized single-blind trial to evaluate the safety profile of Tralement versus a fixed-dose trace element product of zinc, copper, and selenious acid in adult patients who are expected to require at least six-months of home parenteral nutrition.

This study will enroll new prescribed home parenteral nutrition users, i.e. a patient enrolled in the study within six weeks of initiating first-time use of parenteral nutrition requiring trace element additives. Note: a portion of patients who meet inclusion criteria may have received parenteral nutrition in an inpatient setting before discharge home.

Eligible participants who satisfy the inclusion requirements and no exclusion criteria will be consented to participate in this study and enter the screening study phase.

The screening evaluation will be conducted within 5 days of the dose administration of study drug. Study participants meeting entry criteria of normal brain MRI and laboratory manganese concentrations (whole blood/plasma/serum/RBC) will begin study drug on Day 1.

Participants will undergo 2 additional post-baseline brain MRI scans at Months 3 and 6 and have 5 separate neuropsychological tests at Day 1, Month 3, and Month 6. Additional clinical monitoring including safety and laboratory assessments will occur during the 6-month opt-in extension study.

All patients in each assigned trace element parenteral nutrition group will have parenteral nutrition formulations evaluated for manganese content at Day 1, Month 1, Month 3, and Month 6.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

108 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

Triple (Participant, Care Provider, Outcomes Assessor)

Primary Purpose:

Treatment

Official Title:

A Randomized, Single-blind, Trial of Tralement Versus a Fixed-dose Trace Element Combination Product of Zinc, Copper, and Selenious Acid to Evaluate Manganese Safety in Adult Patients Requiring Long-term Parenteral Nutrition

Anticipated Study Start Date :

Dec 31, 2022

Anticipated Primary Completion Date :

Oct 31, 2025

Anticipated Study Completion Date :

Dec 4, 2026

Arms and Interventions

Arm	Intervention/Treatment
Active Comparator: Tralement This study will enroll new prescribed home parenteral nutrition users, i.e. a patient enrolled in the study within six weeks of initiating first-time use of parenteral nutrition formulation requiring trace element additives. Note: a portion of patients who meet inclusion criteria may have received parenteral nutrition in an inpatient setting before discharge home.	Drug: Tralement Tralement with Manganese Sulfate Other Names: manganese sulfate, zinc sulfate, copper sulfate, and selenious acid
Active Comparator: a fixed-dose trace element combination product of zinc sulfate, copper sulfate, and selenious acid This study will enroll new prescribed home parenteral nutrition users, i.e. a patient enrolled in the study within six weeks of initiating first-time use of parenteral nutrition formulation requiring trace element additives. Note: a portion of patients who meet inclusion criteria may have received parenteral nutrition in an inpatient setting before discharge home.	Drug: Fixed-dose trace element combination product of zinc, copper, and selenious acid Tralement without Manganese Sulfate

Arm

Intervention/Treatment

Active Comparator: Tralement

This study will enroll new prescribed home parenteral nutrition users, i.e. a patient enrolled in the study within six weeks of initiating first-time use of parenteral nutrition formulation requiring trace element additives. Note: a portion of patients who meet inclusion criteria may have received parenteral nutrition in an inpatient setting before discharge home.

Drug: Tralement

Tralement with Manganese Sulfate

Other Names:

manganese sulfate, zinc sulfate, copper sulfate, and selenious acid

Active Comparator: a fixed-dose trace element combination product of zinc sulfate, copper sulfate, and selenious acid

This study will enroll new prescribed home parenteral nutrition users, i.e. a patient enrolled in the study within six weeks of initiating first-time use of parenteral nutrition formulation requiring trace element additives. Note: a portion of patients who meet inclusion criteria may have received parenteral nutrition in an inpatient setting before discharge home.

Drug: Fixed-dose trace element combination product of zinc, copper, and selenious acid

Tralement without Manganese Sulfate

Outcome Measures

Primary Outcome Measures

To assess brain deposition of manganese in Tralement versus a fixed-dose trace element product of zinc, copper, and selenious acid. [6 Months]
Change from baseline in basal ganglia index (BG-index) as determined by T1-weighted brain MRI images.

Secondary Outcome Measures

To assess the efficacy & safety of Tralement versus a fixed-dose trace element product of zinc, copper, and selenious acid. [6 Months]
Change from baseline in blood (plasma/serum/RBC) manganese levels assessed

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 80 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Adult (≥18 to ≤80 years of age) participants able to provide informed consent.
Male and female participants who are new users to home parenteral nutrition as a source of trace elements when oral or enteral nutrition is not possible, insufficient, or, contraindicated.
Anticipated duration of home parenteral nutrition use is 6 months or greater.
A normal baseline brain MRI scan.
A normal blood manganese concentration.
Ability to undergo additional 2 brain MRI scans over the six-month study period (Sedation, if appropriate, to be determined by the Principal Investigator's study site, institutional review board recommendations).
Definitive contraception for females of reproductive age.

Exclusion Criteria:

Prior parenteral nutrition therapy.
Hypersensitivity or allergy to zinc or copper.
History of occupational exposure to manganese and documented by laboratory test results.
Baseline ferritin ≥300 ng/mL or below 100 ng/mL.
Baseline transferrin saturation (TSAT) ≥45 % or below 20%.
Prior or current cholestatic liver disease defined as a clinical condition associated with decrease in bile flow due to impaired secretion by hepatocytes or to obstruction of bile flow through intra-or extrahepatic bile ducts.
Liver function studies with transaminases greater than two-fold normal or total bilirubin >2 mg/dL.
Brain MRI exclusion criteria: MRI-unsafe metal implants, claustrophobia.
Known excess environmental exposure to manganese.
Less than 1-year expected survival, as anticipated by their primary provider.
Current participation in another clinical trial.
Females in pregnant state.